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The phase shift hypothesis 
inter depression (seasonal affective disorder,or
SAD) has proved to be a useful model for evaluating the
role of circadian rhythms in psychiatric and sleep disor-
ders.The successful treatment of the first patient,
1 as well
as the first controlled study using bright light,
2 assumed
SAD to be a disorder of seasonal biological rhythms.
Both studies were based on the finding that bright light
could suppress melatonin production in humans.
1
Accordingly,bright light exposure was scheduled in the
morning and late afternoon/evening in order to mimic a
spring photoperiod.The investigators involved in these
early studies diverged into two groups:our group focused
on a circadian approach to SAD
3 while the other group
did not.
4,5The circadian approach was based on the phase
shift hypothesis (PSH) which states that most patients
with SAD become depressed in the winter, at least in
part because of a phase delay in circadian rhythms rela-
tive to the sleep/wake cycle.
6-9The PSH further postulates
that a smaller subgroup of SAD patients becomes
depressed in the winter because of a phase advance.
In 1987,based on our hypothesized phase response curve
(PRC) to light and prior preliminary light studies in
humans,we reported that bright light scheduled in the
morning causes a phase advance (a shift to an earlier
time) and that bright light scheduled in the evening
causes a phase delay (a shift to a later time), using the
dim light melatonin onset (DLMO,that is,the time of the
beginning of melatonin production in dim light) as the
marker for circadian phase position.
8We also reported
that seven of eight SAD patients preferentially
responded to the antidepressant effects of morning light,
whereas one patient preferentially responded to evening
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The finding that bright light can suppress melatonin pro-
duction led to the study of two situations, indeed, models,
of light deprivation: totally blind people and winter depres-
sives. The leading hypothesis for winter depression (sea-
sonal affective disorder, or SAD) is the phase shift hypoth-
esis (PSH). The PSH was recently established in a study in
which SAD patients were given low-dose melatonin in the
afternoon/evening to cause phase advances, or in the morn-
ing to cause phase delays, or placebo. The prototypical
phase-delayed patient, as well as the smaller subgroup of
phase-advanced patients, optimally responded to mela-
tonin given at the correct time. Symptom severity improved
as circadian misalignment was corrected. Circadian mis-
alignment is best measured as the time interval between
the dim light melatonin onset (DLMO) and mid-sleep. Using
the operational definition of the plasma DLMO as the inter-
polated time when melatonin levels continuously rise above
the threshold of 10 pg/mL, the average interval between
DLMO and mid-sleep in healthy controls is 6 hours, which
is associated with optimal mood in SAD patients.
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:291-300.
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8The combination of morning and evening bright
light counteracted each other.There was a statistically
significant,but small,delay in the DLMO of the patients
compared with the controls at baseline.The clinical rec-
ommendations following this report published 20 years
ago
9 remain state-of-the-art and unchanged,except that
light intensity can be increased to 10 000 lux, offering
some shortening of minimal exposure duration.
Accordingly, these recommendations are reprinted in
Table I. SAD patients and controls were phase shifted
with bright light according to Figure 1 (which also
includes how to use melatonin administration to cause
similar phase shifts).
The dim light melatonin onset
The dim light melatonin onset (DLMO) is now the most
commonly used marker for circadian phase position in
humans.
11 Either plasma or saliva is collected usually every
30 minutes between 6 PM and bedtime.
12,13The current rec-
ommendation for dim light is light that is too dim to allow
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Selected abbreviations and acronyms
PSH phase shift hypothesis
DLMO dim light melatonin onset
SAD seasonal affective disorder
PRC phase response curve
PAD phase angle difference
Table I. Treatment guidelines for patients with seasonal affective disorder.
Adapted from ref 9: Lewy AJ. Treating chronobiologic sleep and mood disor-
ders with bright light. Psychiatric Annals.  1987;17:664-669. Copyright ©
Charles Slack 1987.
Treatment guidelines for patients with seasonal
affective disorder
• If patients do not have early-morning awakening, schedule
1 to 2 hours of 2500-10 000 lux exposure immediately upon
awakening.
• If patients begin treatment on the weekend, they may not
have to rise earlier to accommodate the morning light
exposure; early rising may retard the response for a few days.
• The response begins 2 to 4 days after beginning light 
therapy and is usually complete within 2 weeks.
• These patients should minimize any advance in their sleep
time and should avoid bright light in the evening.
• If patients do not respond to treatment, they may need a
longer duration of morning light.
• If patients respond only transiently or begin to complain of
early morning awakening or severe fatigue in the evening,
they may be becoming overly phase advanced due to too
much morning light. The duration of morning light should
be reduced but still begun immediately upon awakening
or some late evening light exposure could be added.
• Some patients may respond to an immediate “energizing”
effect of bright light exposure (this may be a placebo
effect), which if not administered too late in the evening
might be helpful.
• Once a response has been achieved, the duration and 
frequency of light exposures can be reduced. Always begin
light exposure immediately upon awakening or a little
later if patients become overly phase advanced.
• If there is still no response, a trial of evening bright light
(7-9 pm) may be necessary. These patients should minimize
any delay in their sleep time and should avoid bright light
in the morning.
• Appropriate precautions should be taken to avoid any 
possibility of eye discomfort or injury (eg, an eye history
and exam if indicated, instructions never to stare at the
sun, use of safe artificial light sources, and recommenda-
tion of follow-up checkups).
Figure 1. Use of bright light and low-dose melatonin to treat circadian
phase disorders.
Adapted from ref 10: Lewy AJ, Sack RL. The role of melatonin and light in
the human circadian system. In: Buijs R, Kalsbeek A, Romijn H, Pennartz C,
Mirmiran M, eds. Progress in Brain Research. Vol. 111, Hypothalamic
Integration of Circadian Rhythms. Amsterdam: Elsevier; 1996:205-216.
Copyright © Elsevier 1996
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Dim light should begin at about 5 PM.The DLMO can be
operationally defined as the interpolated time when mela-
tonin levels continuously rise above 10 pg/mL in plasma
or 3 pg/mL in saliva.In some cases,thresholds of 2 pg/mL
in plasma and 0.7 pg/mL in saliva are used;melatonin usu-
ally reaches these thresholds about 1 hour earlier than the
10 pg/mL (3 pg/mL) thresholds (Figure 2). The DLMO
appears to be a better marker for circadian phase position
than core body temperature,even when the latter is mea-
sured in a constant routine.
11 Furthermore,posture,sleep,
activity, and meals do not need to be controlled when
using the DLMO as a marker for phase position of the
endogenous circadian pacemaker. Salivary DLMOs
obtained in the home may soon become a standard pro-
cedure for the clinician.Space constraints do not permit a
critical review of the literature in which the DLMO was
initially considered to be the marker of just one compo-
nent of a complex circadian oscillator.
14-17
Testing the PSH using melatonin
administration
In order to provide a critical and falsifiable test of the
PSH, we administered melatonin to cause phase shifts
and thus avoided the large placebo component that
accompanies light treatment.According to the melatonin
PRC,
18,19 melatonin administered in the morning (AM)
causes a phase delay,and melatonin administered in the
afternoon/evening (PM) causes a phase advance.That is,
the melatonin PRC is about 12 hours out of phase with
the light PRC. Therefore, according to the PSH, most
SAD patients should preferentially respond to PM mela-
tonin.After a baseline week in which subjects were per-
mitted to sleep only between consistent bedtimes and
wake times of their choosing and a baseline DLMO
assessment,subjects were assigned to one of three regi-
mens (AM melatonin, PM melatonin, or placebo cap-
sules only).The melatonin dose varied slightly according
to the year and was divided into 3 to 4 capsules,2 hours
apart;the total dose was 0.225 to 0.3 mg per day,depend-
ing on the year.
20 Patients took 7 to 8 capsules per day,
depending on the year.At the end of the third treatment
week, capsules were stopped and the next day a post-
treatment DLMO assessment was undertaken.The 29-
item SIGH-SAD (21-item Ham-D plus eight items char-
acteristic of SAD) was administered weekly for 3 weeks.
When this study was initially formulated,it was thought
that the phase-advanced subgroup was too small to sig-
nificantly influence,testing the hypothesis that PM mela-
tonin would be more antidepressant than AM melatonin.
This may explain why there was no statistically signifi-
cant difference between these two treatments.However,
more informative findings were revealed after phase typ-
ing,based on an operational definition of normal phase
alignment as a 6-hour interval between the DLMO and
midsleep,that is,a phase angle difference (PAD) of 6 h
(Figure 3).Although the clock time of a phase marker is
Phase shift hypothesis in winter depression - Lewy et al Dialogues in Clinical Neuroscience - Vol 9 . No.3 . 2007
293
Figure 2. The dim light melatonin onset (DLMO) in plasma is operationally
defined as the interpolated time when melatonin levels contin-
uously rise above the threshold of either 10 pg/mL or 2 pg/mL
(which usually occurs about 1 hour earlier). In this figure the
DLMO2 is at about 20:30 and the DLMO10 is at about 21:30.
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Figure 3. Schematic diagram of normal phase relationships (rounded to the
nearest integer) between sleep phase markers, the 10 pg/mL
plasma dim light melatonin onset (DLMO) and the core body tem-
perature minimum derived from historical controls. A DLMO-mid-
sleep phase angle (PAD) difference of 6 h is the hypothesized inter-
val for optimal circadian alignment in SAD (seasonal affective
disorder) patients. Sleep times were determined using actigraphy. 
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A. 2006:103:7414-
7419. Copyright © National Academy of Sciences 2006
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(8 hours)important, PAD is more useful because: (i) it removes
confounding effects from sleep/wake cycles that occur at
the different times;(ii) it is almost impossible for subjects
or their raters to infer PAD from knowledge of sleep
times;and (iii) psychiatric symptoms are more likely to
be related to internal circadian misalignment.Plotting
baseline SIGH-SAD scores against PAD revealed a sta-
tistically significant (P=0.003) parabola with an R
2 of 0.17
and a minimum (vertex) of PAD 5.88 h (Figure 4). In
psychiatric studies,an R
2 of 0.17 is considered meaning-
ful, given the inherent noise in behavioral ratings. Six
hours was hypothesized to be the “sweet spot”(the ther-
apeutic interval representing optimal mood),because this
is the average PAD for healthy controls.PAD 6 could be
used to operationally distinguish at baseline those sub-
jects who were phase delayed (PAD ≤6) from those sub-
jects who were phase advanced (PAD >6).The parabola
revealed greater depression severity in 68 subjects who
deviated from PAD 6 (in either direction).
Using PAD 6 at baseline to retrospectively phase type
subjects,analyses revealed that the prototypical phase-
delayed group represented only two thirds of the sub-
jects.Post-treatment,the parabola was statistically sig-
nificant for the prototypical delayed group (R
2=0.19;
P=0.002;minimum =6),whereas the group as a whole has
a less significant parabolic fit (R
2=0.11;P=0.02;minimum
=6). Eleven subjects in the prototypical group (that is,
those who were phase delayed at baseline) had been
assigned to PM melatonin (the equivalent of morning
light, the treatment of choice). A plot of their SIGH-
SAD scores against PAD revealed an R
2 of 0.65,P<0.001
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Figure 4. Pretreatment SIGH-SAD depression score as a function of PAD
(the interval between the DLMO and midsleep, as shown in
Figure 3). (The circled data point, from a 36-year-old female SAD
subject who was assigned to placebo treatment, was the only
one that met outlier criteria [z =3.02] and was therefore
removed from all subsequent analyses and did not substantially
affect any of the above findings [no outliers were detected in
any other analyses].) The parabolic curve (minimum =5.88) indi-
cates that PAD accounts for 17% of the variance in SIGH-SAD
scores (F [2, 65] =6.43). A significant linear correlation was found
for the absolute deviation from the parabolic minimum (r =0.39,
R
2 =0.15, df =65, P =0.001), confirming the validity of the par-
abolic curve fit. SAD, seasonal affective disorder; PAD, phase
angle difference
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A. 2006:103:7414-
7419. Copyright © National Academy of Sciences 2006
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Figure 5. Post-treatment SIGH-SAD score as a function of PAD. The par-
abolic curve (minimum =6.18) indicates that PAD accounts for
11% of the variance in SIGH-SAD scores [F (2, 65)=3.96] for all
subjects and 19% for phase-delayed subjects [F (2, 45)=5.19].
Absolute deviations from the parabolic minima (6.18 and 5.85,
respectively) were statistically significant (advanced and delayed
subjects: r=0.29, R
2=0.09, df =65, P=0.02; delayed subjects:
r=0.48, R
2=0.23, df =65, P=0.001). SAD, seasonal affective dis-
order; PAD, phase angle difference
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A.
2006:103:7414-7419. Copyright © National Academy of Sciences 2006
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(see Figure 4)and parabolic minimum of 6 (Figure 5).That is,65% of
the variance in the behavioral ratings could be explained
by the circadian misalignment component.Patients who
became overly phase advanced on the PM melatonin and
shifted across the sweet spot were more depressed than
those who had shifted closer to PAD 6 (Figure 6).
In this figure (which also includes prototypical patients
treated with AM melatonin and placebo),we did not find
a statistically significant linear correlation,as reported by
the Terman research group with respect to the decrease
in depression ratings change scores plotted against phase
advances in the DLMO.
22Therefore,while there is some
consistency between their study and ours,there are some
clear differences leading to differing treatment recom-
mendations. Terman group claims the key to under-
standing the circadian mechanism of light lies in its abil-
ity to cause a phase advance; the greater the phase
advance,the greater the antidepressant effect.This does
not take into account the possibility that some patients
may do better with evening light so as to provide a cor-
rective phase delay.Furthermore,the Terman group rec-
ommends that patients awaken earlier than usual in
order to schedule light at an earlier circadian time.
However,an earlier wake time would shorten PAD,and,
according to our findings,would compromise light’s anti-
depressant effect in the prototypical phase-delayed
patient. Moreover, we would predict that these proto-
typical patients would do less well if overly phase
advanced by light scheduled too early;it had been known
for some time that as long as the light was not scheduled
too many hours before dawn,the earlier light exposure
was scheduled relative to the DLMO,the greater was its
phase-advancing effect.
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Figure 6. Post-treatment SIGH-SAD score as a function of PAD in delayed
subjects. (The parabolic curve and related statistics for the
delayed subjects are provided in Figure 4). The linear correlation
between PAD and SIGH-SAD score (diagonal hatched line) did
not reach statistical significance, confirming that the parabolic
curve in Figure 4 for delayed subjects (R2=0.19, P=0.009) is the
better fit for these data. Directional linear correlations for under-
and overshifters (to the right and left of PAD 6, respectively) were
both statistically significant. The parabolic curve for subjects
receiving PM melatonin indicates that PAD accounts for 65% of
the variance in SIGH-SAD scores (F [2, 8] =7.57; minimum
=5.56); the correlation between the absolute deviation from the
parabolic minimum was also statistically significant (r=0.75,
R
2=0.56, df=8, P=0.01). SAD, seasonal affective disorder; PAD,
phase angle difference
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A. 2006:103:7414-
7419. Copyright © National Academy of Sciences 2006
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Figure 7. Percent change in SIGH-SAD score as a function of net change
in absolute deviation toward and away from PAD 6 in PM mela-
tonin treated advanced and delayed subjects. Pretreatment vs
posttreatment shifts with respect to PAD 6 account for 35% of
the variance. SAD, seasonal affective disorder; PAD, phase angle
difference
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A. 2006:103:7414-
7419. Copyright © National Academy of Sciences 2006
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r = 0.59, r2 = 0.35,
df = 20, P = 0.004In our study, we also compared SIGH-SAD change
scores versus changes in PAD (Figure 7). This figure
requires some explanation.If a subject had a pretreat-
ment PAD of 4 and a post-treatment PAD of either 5 or
7,this would represent a change closer to PAD 6 of 1.If
the same subject had a post-treatment PAD of 8, this
would represent a change closer to PAD 6 of 0. If the
same subject had a post-treament PAD of either 9 or 3,
this would represent a change closer to PAD 6 of -1,that
is, the PAD is 1 hour further away from PAD 6, after
treatment than before treatment.In this analysis,it does
not matter whether the deviation from 6 is in one direc-
tion or the other,given what was found in the previous
analyses, ie, that subjects were more depressed as the
deviation from 6 increased in either direction. In the
change-score figure,we plotted pre- vs post-treatment
percent change in SIGH-SAD score against the pre- vs
post-treatment change closer to or further away from
PAD 6 in all patients who received either AM melatonin
(administered to cause a phase delay) or PM melatonin
(administered to cause a phase advance).The prediected
linear regression was highly significant (R
2=0.345,r=0.59,
P=0.004).
Thus,SAD may be the first psychiatric disorder in which
symptom severity has been demonstrated to correlate
with a physiological marker before and in the course of
treatment in the same patients.Accordingly, circadian
misalignment may constitute a surrogate marker for the
symptoms of SAD.The above analyses also indicate that
circadian misalignment seems to be the causal term in
the correlation with symptom severity.This remarkable
finding is further confirmed by retrospectively compar-
ing the behavioral response to the correct treatment vs
the incorrect treatment or placebo. Patients who were
phase delayed at baseline and were assigned to PM mela-
tonin received the correct treatment, while those who
were assigned to AM melatonin received the incorrect
treatment;patients who were phase advanced at baseline
and were assigned to AM melatonin received the correct
treatment,while those who were assigned to PM mela-
tonin received the incorrect treatment.The pre- to post-
treatment decrease in depression ratings was 20% more
in the correctly treated groups as compared with the
other two groups,which is remarkably impressive for a
fixed-dose trial of an antidepressant (Figure 8).The most
conservative effect size was 0.61, which also is quite
robust for an antidepressant.Given that most studies of
antidepressants cannot disguise side effects and that
melatonin was administered in such a way that sleepi-
ness, its only side effect, was not present, melatonin
appears to be of enormous therapeutic value,particularly
once the dosing regimen is optimized.We used melatonin
only as a means to test the PSH for light and the inclu-
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Figure 8. Percent change in (SIGH-SAD) depression score after correct
treatment, incorrect treatment, and placebo, as well as incorrect
treatment and placebo combined (correct treatment, such as
giving PM melatonin to phase-delay SAD patients, etc; see text
for details of the composition of these treatment groups).
Baseline SIGH-SAD scores for the three treatment groups (cor-
rect treatment, incorrect treatment, and placebo) were 28.9+1.0,
28.8+1.3, and 26.6+1.4, respectively. The Kruskal–Wallis H test
(χ
2=5.83, df=2, P=0.05) was statistically significant, but not the
one-way ANOVA (F =2.96 on [2, 65], P=0.06). By using the
Welch two-sample t test to compare differences in the change
scores of the correct-treatment group with those of the other
groups, correct treatment significantly decreased depression rat-
ings more than the other groups: incorrect (19.1%: t =2.09, df
=40.8, P =0.04); placebo (20.9%: t =2.60, df =34.2, P =0.01);
the latter two groups combined (19.9%: t =2.65, df =32.1, 
P =0.01). Pretreatment to post-treatment percent changes were
significant for all groups: correct (t =5.43, df =16, P <0.001),
incorrect (t =2.20, df =26, P =0.04), placebo (t =2.50, df =23, 
P =0.02), and the latter two groups combined (t =3.25, df =50,
P =0.002). Effect sizes (ES) are shown for pretreatment to post-
treatment percent change scores for each group; also shown are
the more conservative ES for differences in change scores
between the correct treatment group and the other groups.
(Before phase typing, percent change in the PM treated group
was -28.5 + 5.6, and percent change in the AM treated group
was -15.5 + 8.0, although there were no statistically significant
differences between the three treatment groups in percent
changes in SIGH-SAD scores [see above]). SAD, seasonal affec-
tive disorder
Adapted from ref 20: Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circa-
dian basis of winter depression. Proc Natl Acad Sci U S A. 2006:103:7414-
7419. Copyright © National Academy of Sciences 2006.
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ES=0.46sion of AM melatonin was primarily as a control for PM
melatonin. Future studies should continue to use the
instructions we provided to the patients which minimized
their expectations and helped to lessen the placebo
response (about 13%,compared with the usual 30% in
antidepressant studies).
Circadian alignment appears to cause at most about 35%
to 65% of the variance in symptom severity in SAD.The
PSH may also be applied to sleep and other psychiatric
disorders.The PSH for these other disorders suggests
that they are caused at least in part by a phase shift in cir-
cadian rhythms as marked by the DLMO with respect to
the sleep/wake cycle. While we regard the PSH con-
firmed in SAD, the PSH remains to be tested in other
sleep and psychiatric disorders.
In our recent study,
20 we reported that the weekly SIGH-
SAD ratings continuously declined over the 4 weeks of
the study only in the correctly treated group.These are
plotted in the figure along with those of the incorrectly
treated group combined with the placebo group; the
slopes (not shown) are significantly different (Figure 9).
The treatment response appears to be clinically relevant,
if not statistically significant,at weeks 1 and 2.Patients
who can sense improvement soon after beginning treat-
ment are more likely to comply and continue until the
maximum benefit is achieved.This is a serious problem
with antidepressants,along with their accompanying side
effects.
Using the correlation with phase angle
difference (PAD) to refine 
symptom assessment
We are in the process of analyzing the data for the purpose
of determining which of the 29 items of SIGH-SAD
account for the statistically significant findings for all of
the main analyses of our recent study.
20 Unexpectedly,the
group of eight additional SAD items was not statistically
significant when used instead of the 29-item scale.This sug-
gests that nonseasonal major depressive disorder,as mea-
sured by the 21-item HAM-D,might have a substantial cir-
cadian component related to the PSH.Furthermore,we
have found that all of the main analyses using just three
items substituted for the entire scale (that has a tenfold
greater range) results in almost identical findings.These
three items on 1-5 scales were:(i) self-reported symptoms
of depression;(ii) self-reported symptoms of anxiety;and
(iii) objective assessment of agitation of the subject by the
rater at the time of the interview.Thus,anxiety disorders
and mixed depressive/anxiety disorders should be evalu-
ated for the PSH. Since depression and anxiety are fre-
quently a part of sleep disorders,sleep disorders should also
be tested for the PSH,as well as substance abuse disorders.
As these iterative analyses proceed,we might be able to
define a circadian endophenotype.However,we hesitate
to use this term,as the range in PAD in healthy controls is
the same as in our SAD patients,and the means are not
much different.Therefore,the circadian component is a
necessary but not sufficient cause of SAD.Why some peo-
ple become symptomatic when their DLMO becomes
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Figure 9. Previously unpublished analyses based on data from the study
by Lewy et al, 2006.
20 SIGH-SAD and HAM-D scores of the
groups receiving melatonin treatment given at the correct time
vs. the incorrect time or placebo are shown by week. Although
a two-sample t-test showed significant differences in the SIGH-
SAD scores of the treatment groups only at week 3 (P=0.04),
the response appears to start between week 1 and week 2. A
two-sample t-test showed significant differences in the HAM-D
scores of the two groups beginning at week 2 and increasing at
week 3 (P =0.05, P =0.03, respectively), though these differences
are also apparent at week 1. Additionally, regressions were run
over the SIGH-SAD and HAM-D scores (P =0.04 and P =0.03,
respectively) of each individual’s weekly assessments, and a two-
sample t-test confirmed that the slopes of the subjects receiving
correctly-timed melatonin were different from those receiving
incorrectly-timed melatonin or placebo. SAD, seasonal affective
disorder
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Correctdelayed or advanced with respect to mid-sleep while oth-
ers do not is an important research question.However,the
answer to this may not affect treatment, and would not
diminish the clinical importance of the circadian compo-
nent in SAD:no matter how many necessary-but-not-suf-
ficient causes there may be,correction of just one of these
could produce a successful clinical outcome.
Implications for analyses of extant
and new data sets
It is hoped that the work presented here will alert
researchers to another way of conceptualizing a biological
marker,in addition to the current concept of using a bio-
logical marker to distinguish between patients and healthy
controls,which can often be made by merely taking a good
history, that is, identifying patients who are anxious,
depressed,obsessive-compulsive,paranoid,psychotic,sub-
stance abusers or poor sleepers,etc.Indeed,a symptom
severity biological marker may be more useful than a
chemical test for a DSM diagnosis,particularly if the for-
mer informs the type of treatment and provides a way of
monitoring treatment in addition to assessing subjective
and objective signs and symptoms.Given how relatively
inexpensive and noninvasive the salivary DLMO is com-
pared with other markers,neuroimaging for one example,
and given how safe and inexpensive low-dose melatonin
and light are compared with most other allopathic treat-
ment modalities, there is ample justification for future
investment in circadian research.
Our recent study
20 establishes the PSH and the circadian
component as a necessary but not sufficient cause of a sub-
stantial component of SAD,as well as a biological marker.
It is hoped that the three criteria met by the circadian com-
ponent for the latter designation will clarify what is impor-
tant for other biological markers to demonstrate,some-
thing like Koch’s postulates.We
22 have recently described
these;in the same patients:
• Symptom severity correlates with the biological marker
before treatment.
• Symptom severity correlates with the biological marker
in the course of treatment.
• Symptom change scores in symptom severity correlate
with the change in the biological marker.
In our recent study,
20 we concluded that (in order of cer-
tainty):
The prototypical SAD patient is phase delayed,whereas a less
well defined subgroup may be phase advanced;(ii) the circa-
dian component (at least for the prototypical patients) is sub-
stantial,and it is consistent with the PSH and a hypothesized
therapeutic window for optimal circadian alignment;and (iii)
the work presented here will be useful as a template for rean-
alyzing extant data sets and for implementing new studies of
nonseasonal depression,as well as other sleep and psychiatric
disorders,in which a circadian component might be present.
Accordingly,we tested three a priori hypotheses using
the extant data from our 1998 SAD light treatment study.
We restricted our analyses to the baseline data due to the
known profound placebo component associated with
light. Using the DLMOs as provided in the data set as
well as diary-recorded sleep onset and offset times aver-
aged across the 7 days of the baseline week,we tested the
following hypotheses,
13 plotting 29-item SIGH-SAD
scores against PAD:
•A parabola but not a linear regression would be statis-
tically significant.
•The minimum (vertex) would occur at PAD 6,rounded
to nearest integer.
•Two-thirds of the patients would be phase delayed
(PAD ≤6).
The results confirmed our three hypotheses, as can be
seen in Table II. For disorders other than SAD,PAD 6
may not necessarily represent optimal circadian align-
ment. However, it is nevertheless important to opera-
tionally define the circadian alignment in terms of the
interval between DLMO and midsleep. It may also be
heuristically useful to consider PAD 6, or some other
therapeutic window,in disorders other than SAD.
Once again,we encourage other researchers to make use
of this work in reanalyzing extant data sets and in the
design of future studies. Interestingly, we noticed that
Figure 2 of the Terman paper
21 contained data from which
the proportion of phase delayed vs phase advanced
patients at baseline could be estimated. In this figure,
DLMO is plotted against sleep midpoint. The linear
regression equation (r=0.66) is y=1.01x–5.93.Rounding to
the nearest integer this equation becomes y=x–6 (or y–x=-
6).Since y is DLMO and x is mid-sleep,the line estimates
PAD 6.Therefore,all data points to the left of this line are
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Table II. Baseline analyses
23 of the extant data set
24 replicated the results
of the original study.
20
Lewy et al, 2006
20 Replication Study
R
2, PR
2 =.17, P <.003 R
2 =.22, P <.006
Vertex 5.88 h 5.73 h
Z≤6 71% 65%
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probably PAD <6 (phase delayed according to our crite-
ria) and all data points to the right of this line are PAD >6
(phase advanced according to our criteria).Despite the
limitations of this type of analysis,it is clear that the pre-
dominant group of patients are phase delayed and that
there is a smaller, but substantial, subgroup of patients
who we would categorize as phase advanced at baseline,
which is consistent with the findings in our PNAS paper,
20
although their presumably phase-advanced subgroup
appears to comprise more than one third of the patients.
Before closing,we should note that the work of others in
the field of circadian rhythms and depression was recently
reviewed.
25We should also note that agomelatine,a mela-
tonin agonist with serotonergic actions, appears to be
effective in major depressive disorder.
26 Furthermore,at
least animal studies suggest anxiolytic effects.
27These find-
ings are consistent with what we have reported above.
For the clinicians,particularly those practicing in the US,
it is important to note that melatonin is easily available
to consumers without a prescription.Our impression is
that some SAD patients prefer light,some prefer mela-
tonin,and some prefer the combination,at least for the
very shortest days of the year.Until more clinical labs are
capable of measuring melatonin in saliva,clinicians must
proceed without this test and the recommendations of
Table I remain state-of-the-art.Since most patients with
SAD are of the phase-delayed type,morning light should
usually be tried first. Failure to respond is apparent
within the first week of treatment, after which bright
light should be switched to the evening.If morning bright
light causes too much of a phase advance,patients will
start to complain of early-morning awakening. ❏
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La hipótesis del cambio de fase para el com-
ponente circadiano de la depresión invernal
El hallazgo que la luz brillante puede suprimir la
producción de melatonina condujo al estudio de
dos situaciones, o mejor dicho modelos, de priva-
ción de luz: las personas totalmente ciegas y los
depresivos invernales. La principal hipótesis para la
depresión invernal (trastorno afectivo estacional,
TAE) es la hipótesis del cambio de fase (HCF). La
HCF se estableció recientemente a partir de los
resultados de un estudio en pacientes con TAE que
recibieron bajas dosis de melatonina en la
tarde/noche para causar un avance de fase, o en la
mañana para provocar retardo de fase, o placebo.
El paciente prototípico con retardo de fase, como
también el pequeño subgrupo de pacientes con
avance de fase, respondieron en forma óptima a la
melatonina administrada en el momento correcto.
La gravedad de los síntomas mejoró en la medida
que se corrigió el desajuste circadiano. El desajuste
circadiano se puede definir mejor como el intervalo
de tiempo entre el inicio de la producción de mela-
tonina con la luz tenue (dim light melatonin onset,
DLMO) y la mitad del sueño. Al utilizar la definición
operacional de la DLMO como el tiempo interpo-
lado cuando los niveles de melatonina se elevan
continuamente sobre el umbral de 10 pg/mL, el
intervalo promedio entre DLMO y la mitad del
sueño en controles sanos fue de 6 horas, lo que se
asoció con un ánimo óptimo en pacientes con TAE.  
L’hypothèse du décalage de phase pour la
composante circadienne de la dépression
hivernale
La découverte que la lumière intense peut inhiber
la sécrétion de mélatonine a mené à l’étude de
deux situations qui sont des modèles de la privation
de lumière : la cécité totale et le trouble affectif sai-
sonnier hivernal (TAS). L’hypothèse d’un décalage
de phase (HDP) est la théorie principale pour le TAS.
Une étude récente a permis de confirmer l’HDP par
administration à des patients ayant un TAS de fai-
bles doses de mélatonine l’après-midi ou le soir
pour provoquer une avance de phase, ou le matin
pour un retard de phase. Un placebo a aussi été
administré. Les patients ayant un retard de phase
caractéristique, ainsi que le sous-groupe plus petit
des patients ayant une avance de phase, ont
répondu de façon optimale lorsque la mélatonine
était administrée au bon moment. La sévérité des
symptômes s’est améliorée quand la désynchroni-
sation circadienne a été corrigée. La meilleure
mesure de cette désynchronisation consiste en l’in-
tervalle de temps entre le début de la sécrétion de
mélatonine en éclairage faible (SMEF) et le milieu
de la durée du sommeil. La définition opération-
nelle de la SMEF consiste au moment (extrapolé) à
partir duquel la concentration plasmatique de
mélatonine reste systématiquement au-dessus du
seuil de 10 pg/ml. Selon cette définition, l’intervalle
moyen entre la SMLF et le milieu de la durée du
sommeil est de 6 h chez les témoins sains, et est
associée à l’humeur optimale chez les patients
ayant un TAS.